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ABSTRACT
Objective: To establish cost-effectiveness of antiepileptic
drug (AED) treatment strategies of newly diagnosed patients
with epilepsy.
Methods: A decision analysis was carried out comparing
effectiveness and treatment cost of six treatment strategies
comprising carbamazepine (CBZ), lamotrigine (LTG), and
valproate (VPA) as ﬁrst-line and second-line drugs. Three
outcome groups were deﬁned: complete success, partial
success, and failure. Data on seizure control and failure due
to adverse effects were derived from the literature. Data on
resource use and costs were collected for each outcome group
by means of a patient survey.
Results: Cost data were obtained from 71 patients. Cost
increased from complete success to failure outcome groups.
The probability of obtaining complete success varied from
64% (VPA–CBZ strategy) to 74% (LTG–VPA strategy). The
strategy LTG–VPA was more effective than the least expen-
sive strategy CBZ–VPA, but at higher costs per additional
effectively treated patient. Probabilistic sensitivity analysis
conﬁrmed these ﬁndings to be robust. Subsequent analysis
showed that changing inclusion criteria used in the selection
of the studies from the literature had a major effect on
cost-effectiveness ratios of the various strategies. The prob-
ability that LTG ﬁrst-line therapy is the most cost-effective
option remains small, even deﬁning a high cost-effectiveness
threshold. Nevertheless, LTG second-line strategies can be
cost-effective depending on the willingness to pay for patient
improvement.
Conclusions: Only a few studies satisﬁed our inclusion
criteria for employment in our decision model. Our model
supports the use of conventional AEDs as ﬁrst-line options
for patients with newly diagnosed epilepsy. LTG second-line
therapy is likely to be the most cost-effective option in case
society is willing to pay more than €6000 for an additional
successfully treated patient. This study also illustrates that,
with the data presently available, the outcome of decision
analysis for AED treatment choice depends on the inclusion
criteria used to select trials. Prospective real-life studies are
needed in which ﬁrst- and second-line treatment strategies are
compared with respect to both effectiveness and costs.
Keywords: cost-effectiveness, decision tree model, epilepsy,
lamotrigine.
Introduction
Carbamazepine (CBZ), phenobarbital, phenytoin, and
valproate (VPA) have been the leading antiepileptic
drugs (AEDs) for more than 30 years. Several new
AEDs have, however, been introduced during the last
decade.
In order to be licensed, these new AEDs had to
demonstrate efﬁcacy as adjunctive therapy in
so-called intractable patients, that is, in patients with
inadequate seizure control despite optimal therapy.
Once a new compound is licensed and has demon-
strated its effectiveness in daily practice, it will often
be compared with the existing compounds in mono-
therapy trials for patients with newly diagnosed epi-
lepsy. Lamotrigine (LTG), one of the new AEDs, has
been involved in several of these comparative mono-
therapy trials [1–4]. A main advantage of LTG over
conventional AEDs seems to be its favorable toler-
ability proﬁle, leading to fewer treatment failures,
fewer cognitive side effects and a better disease-
related quality of life in patients with newly diag-
nosed epilepsy [4–6].
These results may contribute to a more widespread
use of LTG. Nevertheless, the acquisition cost of LTG
is several times higher than that of conventional AEDs.
In this era of constrained health-care resources, health
authorities are beginning to demand economic justiﬁ-
cation for new AEDs. The purpose of this study is
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to establish the cost-effectiveness of LTG in patients
with newly diagnosed epilepsy. In this study, the
cost-effectiveness of LTG is compared with CBZ
and VPA through a decision analytic approach.
Drug-speciﬁc effectiveness data were derived from
randomized clinical trials and observational studies
published in the international literature. Patient data
on cost consumption were collected for patients in one
out of three different outcome groups via a patient
questionnaire.
Six treatment strategies are compared in this study,
that is, CBZ ﬁrst-line monotherapy followed by either
VPA or LTG in case CBZ fails because of either a lack
of seizure control or adverse effects, VPA ﬁrst-line
monotherapy followed by either CBZ or LTG in case
VPA fails because of either a lack of seizure control or
adverse effects, and LTG ﬁrst-line monotherapy fol-
lowed by either CBZ or VPA in case LTG fails because
of either a lack of seizure control or adverse effects.
Methods
Study Design
This article details a cost-effectiveness analysis evalu-
ating ﬁrst- and second-line treatment strategies in
patients with newly diagnosed epilepsy. The analysis
uses a decision tree as a modeling instrument. In accor-
dance with Dutch guidelines on pharmacoeconomic
research, a societal perspective was adopted for the
economic evaluations [7]. The time span comprises the
ﬁrst year of treatment.
Decision Tree Model
A decision tree analysis (software program DATA;
TreeAge Software, Williamstown, MA) was used as a
model to depict potential clinical pathways and out-
comes within the ﬁrst year of treatment. Figure 1
shows the structure of the model. Three ﬁrst-line drugs
are studied: CBZ, VPA, and LTG. Six treatment strat-
egies are evaluated comprising all possible variations
of ﬁrst- and second-line treatment with these three
agents. In the model the effectiveness of the ﬁrst drug is
evaluated after 6 months. When a patient is seizure-
free and does not experience unacceptable adverse
effects, the patient continues with the ﬁrst-line drug for
the remaining 6 months. If there are unacceptable side
effects on the ﬁrst drug, the patient is switched directly
to a second drug in monotherapy. In case of inadequate
seizure control, the second-line treatment is ﬁrst added
to the ﬁrst-line drug. In this case, the ﬁrst-line drug is
withdrawn after 2 months and second-line mono-
therapy is used for the last 4 months of the study.
Thus, the assumption is made that at the end of the
ﬁrst year all patients are in one of three outcome
groups, that is, complete success, partial success, or
failure. Complete success implies the patient being
seizure-free. Partial success is deﬁned as a reduction in
seizure frequency of more than 50% compared with
baseline. Failure is deﬁned as inadequate seizure
control (i.e., less than 50% seizure reduction) or the
occurrence of unacceptable adverse effects.
Decision Model Input
Path probabilities, reﬂecting the effectiveness of the
different treatment strategies, were based on literature
data. A limited number of studies with comparable
study designs reporting effectiveness of these drugs
as ﬁrst-line therapy were selected from the available
full-published comparative monotherapy studies. The
inclusion criteria used for this selection procedure were:
complete success
complete success
failure
unacceptable side effects,
switch to VPA
complete success
phase out CBZ to
monotherapy VPAseizure-free
partial successcontinue combi therapyacceptable seizure reduction
failure
not seizure-free
incomplete seizure reduction,
combination with VPA
failure
CBZ → VPA
VPA → CBZ
 [+] 
VPA → LTG
 [+] 
 CBZ → LTG
 [+] 
LTG → VPA
 [+] 
LTG → LTG
 [+] 
newly
diagnosed
patients with
epilepsy
Figure 1 Decision tree model.The model is shown for the ﬁrst-line strategy carbamazepine (CBZ) followed by valproate (VPA) in case of failure (CBZ
→VPA).The structure of the model applies to all strategies. Circles represent change nodes.Triangles represent outcome groups, in which patients remain
for the duration of the ﬁrst year of treatment. LTG, lamotrigine.
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• study participants had to be more than 12 years of
age with newly diagnosed epilepsy;
• seizures had to be partial and/or generalized
tonic–clonic seizures;
• starting dosages and titration schedules had to be
in accordance with present guidelines;
• evaluation period of at least 24 weeks;
• no dose adjustments allowed during evaluation
period.
From the selected studies, ﬁrst-line probabilities on
seizure freedom, failure due to side effects, and failure
due to insufﬁcient seizure reduction were calculated.
All analyses were performed on a per protocol basis.
Individual probabilities were based on weighted prob-
abilities from the different studies based on their study
size.
Studies reporting effectiveness of these drugs as
second-line therapy were selected from available full-
published studies evaluated in two earlier review
articles [8,9]. The inclusion criteria were:
• titration and taper schedules in accordance with
present guidelines;
• combination period of 8 to 12 weeks;
• monotherapy phase of 8 to 12 weeks.
From the selected studies, second-line probabilities
on seizure freedom, failure due to side effects, and
failure due to insufﬁcient seizure reduction were
calculated.
Collection of Data on Cost
From a societal viewpoint, three sectors can be identi-
ﬁed in which epilepsy-related costs may occur: health-
care sector, patient and family sector, and others [10].
To estimate the cost of epilepsy care in the ﬁrst sector,
data were obtained from the medical records of
patients. Data on costs in the two latter sectors were
collected using patient questionnaires. In this question-
naire, information was collected retrospectively over a
period of 3 months and prospectively the same data
were collected for 6 months following the inclusion
date. Three months is a recommended recall period
for retrospective data collection [11]. Adult epilepsy
patients visiting the outpatient department of neurol-
ogy of the University Medical Centre Nijmegen and
the University Hospital Maastricht could participate.
The treating physicians classiﬁed each patient into one
of the three outcome groups based on seizure fre-
quency. Patients were classiﬁed as complete success
(seizure-free), partial success (more than 50% reduc-
tion in seizure frequency), or failure (less then 50%
seizure reduction).
The daily maintenance doses deﬁned in the decision
model are based on the average doses achieved in the
trials considered, that is, 600 mg for CBZ, 150 mg for
LTG, and 1000 mg for VPA. For LTG used in combi-
nation with CBZ, the daily dose was set at 300 mg.
Cost Valuation
The assignment of unit cost to the various elements of
epilepsy care is based on an instruction document for
economic evaluation in Dutch health care by Oosten-
brink et al. [12]. This document provides guideline
prices relevant for The Netherlands for various items,
such as outpatient clinic visits and hospitalization.
When there is no guideline price for an item, these
items were valued by using ofﬁcial tariff lists for allow-
able reimbursement rates.
Table 1 mentions these cost units and their prices.
All ﬁgures were updated to January 2002 according
to the rate of inﬂation. Inﬂation was measured by the
Table 1 Unit cost per item
Cost item Cost measure Unit cost (€) Source
Health-care sector
GP services Cost per visit 16.7 Guideline price
Physician services Cost per visit 46.1 Guideline price
Hospital services
Neurologic ward Cost per admission day 304.3 Guideline price
Ambulance Cost per trip 265.2 Guideline price
Diagnostics
Laboratory Cost per procedure 4.4 Tariff*
Imaging (EEG, CT, MRI) Cost per procedure 95.6 Tariff†
Drug therapy Cost per month Tariff
CBZ 600 mg 9.7
LTG 150 mg 69.6
VPA 1000 mg 15.9
Patient and family sector
Unpaid care Cost per hour 8.9 Guideline price
Other sectors
Absence of work Cost per day 106.5 Guideline price‡
*Weighted composition of tariffs from different laboratory investigations.
†Weighted composition of tariffs from different imaging tests.
‡Weighted composition of different ages.
CBZ, carbamazepine; CT, computed tomography; EEG, electroencephalogram; GP, general practitioner; LTG, lamotrigine; MRI, magnetic resonance imaging; VPA, valproate.
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Consumer Price Index published by Statistics Nether-
lands (http://www.cbs.nl). All costs were expressed in
euro (€).
Cost-Effectiveness Analysis
The analysis of the decision tree model results in prob-
abilities of a theoretical patient to end up in one of
three outcome groups, that is, complete success, partial
success, or failure, the so-called path probabilities.
Based on these path probabilities, the expected cost of
each of the six strategies was determined. General
principles of cost-effectiveness analysis were applied to
these results [10]. First, it was determined whether
certain strategies were dominated by other strategies.
A dominated strategy is more costly, but less effective
than another strategy. For nondominated strategies,
the cost-effectiveness analysis combines the expected
costs with the probability of complete success, that is,
the incremental cost-effectiveness ratio (ICER). Begin-
ning with the least costly strategy, nondominated alter-
natives were compared with calculate incremental
ratios. The ICER is calculated as:
mean annual cost per patient
mean annual cost per patie
strategy( ) −2
nt
complete success complete success
strategy 1
strategy 2
( )
( ) − ( )strategy 1
Sensitivity Analysis
Second-order uncertainty of the cost-effectiveness
estimates of the six strategies was investigated by
Monte Carlo simulation techniques. Distributions
were deﬁned for the probabilities and costs used in the
model (complete success, incomplete seizure reduction,
unacceptable side effects). As probabilities are sup-
posed to have a value between 0 and 1, beta distribu-
tions were ﬁtted for all these parameters. For costs
gamma distributions (zero to inﬁnity) were deﬁned.
For deﬁning the gamma distributions, the observed
mean and variance of the total costs in our patient data
were used. The probabilities of complete success and
acceptable seizure for the different drug regimens were
treated as independent binomial distributions using the
total patient numbers and the proportion of success as
shown in Table 2. Of course, the patient outcome
measure complete success was dichotomous and there-
fore, in contrast to the probability of success, was not
part of the probabilistic sensitivity analysis. All six
strategies were evaluated in the simulation that was
performed with 1000 iterations. As a result of the
iterations, for every cost and effectiveness pair of a
strategy, net beneﬁts were calculated for a range of
levels of ceiling cost-effectiveness ratios. For each itera-
tion, a strategy is considered optimal in case of the
highest net beneﬁt and the proportion of the iterations
being optimal is determined for each strategy. Subse-
quently, cost-effectiveness acceptability curves were
drawn for each of the six strategies.
Additional models were designed that, next to the
studies in the initial model, incorporated studies that
did not meet the inclusion criteria used for our initial
model (which will be called model A from here on).
This was done to check for bias introduced by our
inclusion criteria. These additional models will be
called models B–D.
Results
Decision Tree Analysis
A literature search yielded 14 ﬁrst-line monotherapy
trials. Only three of these 14 studies met our inclusion
criteria [2,13,14]. The probabilities for the various
outcome groups derived from these studies are pre-
sented in Table 2. The other studies were excluded for
various reasons. Two studies also concerned patients
that did not have newly diagnosed epilepsy [6,15]. One
study only considered patients older than 65 years of
age [3]. Titration schedules used in two studies were no
longer in agreement with present guidelines [1,4]. The
evaluation period was too short in one study [16]. In
Table 2 Studies incorporated into ﬁrst-line strategies of the decision tree model
Model AED
Patients
(n)
Doses
(mg/day)
Starting
doses
(mg) Titration
Complete
success
(%)
Failure
due to
ADR
(%)
Failure
due to
incomplete
control (%) Reference
A CBZ 101 600 200 200 mg/2 weeks 63 12 25 Reunanen et al. (2)
CBZ 45 Based on
plasma levels
Not mentioned Not mentioned 67 27 6 Kälviäinen et al. (13)
VPA 97 Flexible 300 No ﬁxed scheme 59 11 30 Christe et al. (14)
LTG 98 100 25 25 mg/2 weeks 60 5 35 Reunanen et al. (2)
LTG 106 200 25 25 mg/2 weeks 63 5 32 Reunanen et al. (2)
B CBZ 103 Flexible 200 200 mg/week 48 34 18 Brodie et al. (1)
LTG 107 Flexible 50 50 mg/week 48 19 33 Brodie et al. (1)
C CBZ 141 Flexible 200 First: 200 mg/week
Then: 200 mg/2 weeks
47 17 36 Richens et al. (17)
VPA 140 Flexible 400 400 mg/week 44 6 50 Richens et al. (17)
Model B incorporates the studies of models A and B; model C incorporates the studies of models A and C; model D (not shown) incorporates all studies.
ADR, adverse drug reaction;AED, antiepileptic drug; CBZ, carbamazepine; LTG, lamotrigine;VPA, valproate.
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ﬁve studies the number of patients becoming seizure-
free at the end of the evaluation phase was not
mentioned [17–21].
Two second-line studies met our inclusion criteria
[22,23]. No data were found on probabilities for
second-line VPA or CBZ after failure of LTG. An
assumption was made that these latter probabilities
were the same as for second-line LTG after failure of
VPA or CBZ. No drug-speciﬁc data were found on the
probability of a second drug leading to complete success
after failure of a ﬁrst drug due to side effects. A general
probability for this scenariowas derived from the obser-
vational study byKwan et al. [24]. The probabilities for
second-line treatments are shown in Table 3.
Collection of Data on Cost
Self-reported data on cost were collected from a total
of 71 patients: 30 patients (21 men; mean age
49  19 years) were in the complete success outcome
group, 27 patients (13 men; mean age 43  18 years)
in the partial success outcome group, and 14 patients
(7 men; mean age 54  20 years) in the failure
outcome group. Average monthly costs per patient,
with the exception of drug costs, are presented in
Table 4. Overall, an inverse relation between cost con-
sumption per item and outcome groups was demon-
strated. Patients in the complete success group
appeared to incur the lowest costs (€35.8/month) in
contrast to patients in the failure outcome group
(€130.4/month). The items “hospital services” and
“unpaid care” contributed most to the costs. Lost pro-
ductivity due to absence of work was negligible.
Cost-Effectiveness Analysis
The results of the cost-effectiveness analysis are pre-
sented in Table 5 and ranked in ascending order of
expected costs. The probability of obtaining complete
success varied from 64% (VPA–CBZ strategy) to 74%
(LTG–VPA strategy). The treatment strategy with the
lowest cost, the reference treatment, was CBZ–VPA
with expected annual costs per patient for the ﬁrst year
of treatment of €975 (probability complete success is
68.4%). The treatment strategy LTG–CBZ took up the
highest costs, €2036 annually. The LTG–CBZ strategy
and also the strategies VPA–LTG and VPA–CBZ were
dominated strategies (more expensive and less effec-
tive). Two treatment alternatives, CBZ–LTG and LTG–
VPA, were nondominated strategies. The ICER of
CBZ–LTG relative to the CBZ–VPA strategy is €6079
per additional complete success patient. That of LTG–
VPA relative to CBZ–LTG is €40,422 per additional
complete success patient.
Sensitivity Analysis
Figure 2 shows the cost-effectiveness acceptability
curves of the different strategies and illustrates that
Table 3 Probabilities of second-line drug strategies
Second-line strategy*
Patients
(n)
Complete
success
(%)
Partial
success
(%)
Failure
(%) Comments Reference
CBZ–VPA and VPA–CBZ 95 8 23 69 Assumption:
VPA → CBZ as CBZ → VPA
Brodie and Mumford (22)
CBZ–LTG and LTG–CBZ 63 22 21 57 Assumption:
CBZ → LTG as LTG → CBZ
Jozwiak and Terczynski (23)
VPA–LTG and LTG–VPA 63 32 32 34 Assumption:
VPA → LTG as LTG → VPA
Jozwiak and Terczynski (23)
Second AED after failure of
ﬁrst AED due to side effects
98 34 66 General assumption Kwan and Brodie (24)
*CBZ-VPA: path probabilities of VPA as second-line drug after failure of CBZ as ﬁrst-line drug (see Fig. 1).
AED, antiepileptic drug; CBZ, carbamazepine; LTG, lamotrigine;VPA, valproate.
Table 4 Average breakdown of costs per patient group in euro per month (and ranges)
Cost item Complete success Partial success Failure
Health-care sector
GP services 0 (0–0) 0.5 (0–10.7) 4.9 (0–46.2)
Physician services 8.5 (0.1–35.3) 8.3 (0–46.2) 13.1 (0.1–73.6)
Hospital services 0 (0–0) 17.6 (0–625.5) 54.6 (0–727.6)
Diagnostics (laboratory & imaging) 24.5 (0.2–161.8) 33.8 (0–302.2) 41.0 (0.2–330.0)
Patient and family sector
Unpaid care 2.8 (0–64.5) 67.4 (0–3642.7) 16.8 (0–413.6)
Others
Absence of work — — —
Subtotal* 35.8 127.6 130.4
*The cost of drug therapy is strategy-speciﬁc and therefore not shown in this table.
GP, general practitioner.
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CBZ–VPA has the highest probability of being most
cost-effective in the lower range of the ceiling ratio. In
the higher range of the ceiling ratio, second-line LTG
options have the highest probability to be the most
cost-effective. The ﬁrst-line strategies with LTG as a
ﬁrst-line drug are clearly shown not to be cost-
effective, despite a high cost-effectiveness threshold of
€25,000 per effectively treated patient. Probabilistic
sensitivity analysis conﬁrms these ﬁndings to be
robust.
In a subsequent analysis, the impact of the inclusion
criteria used (to select studies reporting ﬁrst-line path
probabilities) on the outcomes of the cost-effectiveness
model was evaluated. Three additional models were
designed that, next to the studies in the initial model,
incorporated studies that did not meet the inclusion
criteria used for model A (see Table 2). In model B, a
study by Brodie et al. was added to the studies in
model A [1]. This study was not included into model A
because titration schedules for both CBZ and LTG
were not conform present guidelines [25]. Table 6
shows that incorporation of this study leaves the ref-
erence strategy CBZ–VPA unchanged, and that the
strategies CBZ–LTG and LTG–VPA become domi-
nated strategies (where as in model A they were non-
dominated strategies). Model C consists of the studies
included in model A plus a study by Richens et al. [17].
This study was left out of model A for two reasons.
The starting dosage of VPA was rather low compared
with present guidelines, and this resulted in a pro-
longed period before the eventual effect of this drug
could be expected. Furthermore, the number of
patients becoming seizure-free was not clearly men-
tioned in this study and had to be estimated from a
Kaplan–Meier graph. Table 6 shows that incorpora-
tion of this study leaves the reference strategy
unchanged and that the ICER of the LTG–VPA strat-
egy becomes 8021 (whereas in model A the ICER was
40,422). In model D, both the Brodie et al. and the
Richens et al. studies were added to the studies in
model A. Consequently, all ﬁrst-line path probabilities
changed compared with model A. Table 6 shows that
the strategy with the least costs was CBZ–VPA and
that the strategies CBZ–LTG and LTG–VPA were more
Table 5 Cost-effectiveness analysis
Strategy
(model A)
Expected 1-year
cost per patient (€)
Expected
complete success ICER*
CBZ–VPA 975 0.684 Reference
VPA–CBZ 1,111 0.635 (Dominated)
CBZ–LTG† 1,230 0.726 6,079
VPA–LTG 1,255 0.722 (Dominated)
LTG–VPA‡ 1,861 0.742 40,422
LTG–CBZ 2,036 0.706 (Dominated)
*The ICER is calculated relative to the next less costly nondominated strategy.
†Calculation ICER CBZ–LTG: (1230–975)/(0.726–0.684).
‡Calculation ICER LTG–VPA: (1861–1230)/(0.742–0.726).
CBZ, carbamazepine; ICER, incremental cost-effectiveness ratio; LTG, lamotrigine;
VPA, valproate.
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effective compared with this reference strategy. Never-
theless, the strategy CBZ–LTG is extended dominated
by LTG–VPA and the ICER of the LTG–VPA strategy
becomes 11,354.
Discussion
Ideally, an economic evaluation consists of a real-life
study in which both clinical and cost data are
assessed [10,26]. Such a study is not available for
AEDs and therefore we used existing published lit-
erature for estimates of effectiveness and a patient
questionnaire for estimates on cost items. As there is
no randomized trial directly comparing CBZ, VPA,
and LTG, a decision model was used for an indirect
comparison of a number of original, controlled trials.
To strengthen these comparisons, stringent inclusion
criteria to the eligible trials were applied. This
resulted in a limited number of included trials. For
the probabilities of second-line treatment we had to
rely on several assumptions, since only two studies
satisﬁed our predeﬁned inclusion criteria. In our
opinion, it is justiﬁed to assume that the effectiveness
of CBZ and VPA as second-line treatments following
LTG is equal to that of LTG used as a second-line
treatment following CBZ or VPA. The efﬁcacy of a
drug is determined not only by its pharmacodynamic
properties, but also by the stage of treatment at
which it is given and by which drugs were given
earlier. The observational study by Kwan and Brodie
showed that more than 50% of patients become
seizure-free on the ﬁrst drug, whereas the chances of
becoming seizure-free on the second or third drug
rapidly decline thereafter [24]. The LTG substitution
study by Jozwiak and Terczynski showed that the
efﬁcacy of LTG was higher in patients that had not
become seizure-free on VPA, than in patients that
had not become seizure-free on CBZ [23]. Because of
these factors, one would expect the total number of
patients responding to the treatment strategy A, pos-
sibly followed by B, to be equal as the total number
of patients responding to the treatment strategy B,
possibly followed by A. This has actually been dem-
onstrated by two crossover studies in the literature
[27,28].
All models in our study show that CBZ–VPA is the
reference treatment and that there are more effective
treatments, but at considerable costs per extra patient
treated effectively. Assessing levels of uncertainty is
important in cost-effectiveness analysis because of the
assumptions made about the relation between the
intervention and the outcome [29]. This is, however,
rather complicated because the outcome in a cost-
effectiveness analysis is a ratio of two different out-
comes (costs and effects), rather than an estimate of a
single outcome (say, adequate seizure reduction). Sen-
sitivity analysis, preferably probabilistic, is an acceptedTa
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method to evaluate whether the result is robust to
changes in the different parameters involved. This
study shows that it is also important to use transparent
inclusion criteria for data used to build the decision
tree model. In our opinion, Model A is the most appro-
priate model because the titration schedules used in
these studies are up to date and because the results
of these studies were presented clearly. Nevertheless,
the inclusion criteria used were of inﬂuence on the
outcome, especially on the ICER, as the differences
between models A–D show. A limitation of our model
is the fact that the probabilities of complete success
and acceptable seizure were treated as independent
binomial distributions. By employing a Dirichlet dis-
tribution, these probabilities could have been made
conditionally dependent, but a major inﬂuence on our
conclusions is not expected.
In this study, we used a cost questionnaire to obtain
data on cost consumption. The validity of a cost ques-
tionnaire such as ours was assessed previously [30].
This comprehensive questionnaire allows collecting
patient-based costs of epilepsy, as is widely recom-
mended for cost-effectiveness studies [31]. Another
approach to estimate cost items is the use of an expert
panel (Delphi panel), as has been used in previous
economic studies in epilepsy [32,33]. Such a panel
estimates the costs incurred by patients. We believe
that patient-based cost collecting is at least as
adequate, and gives additional valid data. The costs
are assumed to be equal within each of the three
outcome categories, except for drug costs. It seems
reasonable that the frequency of visits to the outpatient
department and of investigations is dependent on the
response to treatment, rather than on the drug with
which this outcome is realized. It also is likely that the
utility within an outcome category is related to that
category, rather than to the drug used.
We found that cost of treatment of patients with
newly diagnosed epilepsy was lowest for the conven-
tional strategy CBZ–VPA. The LTG–VPA strategy,
with ﬁrst-line use of LTG, was more effective but
against considerably higher cost per individual
seizure-free patient in model A. The cost-effectiveness
of LTG monotherapy was compared with CBZ mono-
therapy in one cost minimization study and with
CBZ, phenytoin, and VPA monotherapy in a second
cost minimization study [32,33]. The ﬁrst study was
based on only one comparative monotherapy trial,
while the second study was based on eight different
monotherapy studies. In cost minimization studies,
the efﬁcacy of the respective treatments is assumed to
be equal; the only outcome is treatment cost per
initial strategy and the costs considered are drug
costs, costs of resources employed in the management
of adverse events, and costs associated with therapeu-
tic switching. Both cost minimization studies showed
that LTG is considerably more expensive for newly
diagnosed patients in health service costs incurred.
There are several differences between our study and
these two cost minimization studies: 1) efﬁcacy is not
assumed to be equal in our study; 2) we determined
costs per additionally effectively treated patient in
comparison with the reference treatment; 3) we used
stringent inclusion criteria to yield a sample of com-
parable studies; 4) our sensitivity analysis evaluated
the effects of including further studies instead of
evaluating best-case and worst-case scenarios of
included studies; and 5) we used a patient question-
naire instead of a Delphi panel. Despite differences in
methodology between the approaches, the ﬁndings
are overall rather similar for model A.
Our model supports the use of conventional AEDs
as ﬁrst-line options for patients with newly diagnosed
epilepsy. LTG second-line therapy is likely to be the
most cost-effective option in case society is willing to
pay more than €6000 for an additional successfully
treated patient. Our ﬁndings agree with the technology
appraisal guidance “newer drugs for epilepsy in
adults” from the National Institute for Clinical Excel-
lence (NICE) from the UK [34]. In the NICE guidance,
the newer AEDs like LTG are recommended for the
management of epilepsy in people who have not ben-
eﬁted from treatment with the conventional AEDs, or
for whom the older drugs are unsuitable because of
contraindications, interactions, or the person is a
woman of childbearing potential.
Our study also illustrates that with the data pres-
ently available, the outcome of decision analysis for
drug treatment choice depends on the inclusion cri-
teria used to select trials. Neurologists are counting
on cost-effectiveness data to make rational choices
[35]. Therefore, there is a need for prospective real-
life studies comparing strategies of ﬁrst- and second-
line treatment and incorporating both cost and
outcomes.
Source of ﬁnancial support: This study is part of a research
project on rational use of lamotrigine. This project is granted
by the Dutch National Health Care Insurance Board. Neither
the Health Care Insurance Board nor any other organizations
exerted undo inﬂuence with regard to the results of this study.
The authors have no ﬁnancial binding with any pharmaceu-
tical company.
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